A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Ovarian Cancer
Recurrent Epithelial Cancer of Ovary
Recurrent Epithelial Ovarian Cancer
Recurrent Fallopian Tube Cancer
Peritoneal Cancer
Recurrent Carcinoma of Ovary
Adenocarcinoma of Ovary

Interventions

BIOLOGICAL: Oregovomab
DRUG: Niraparib

Sponsor

CanariaBio Inc.

Collaborators

[object Object]
[object Object]